INTRODUCTION 1
At least half of the world's population is infected with Helicobacter pylori, one of the 2 few microorganisms known to be able to colonize the human stomach. In 10-15% of 3 infected individuals, chronic H. pylori infection causes duodenal ulcers, and infection 4 with H. pylori has been shown to be a strong risk factor for the development of gastric 5 adenocarcinoma and malignant mucosa-associated lymphomas (3, 17, 20) . Although 6 treatment with a combination of antibiotics and a proton pump inhibitor is usually 7 effective in individual cases, limited treatment compliance, rapidly emerging antibiotic 8 resistance, and frequent re-infection with H. pylori in highly endemic countries make 9 vaccination an increasingly attractive alternative or complement to standard therapy. 10 11 Vaccination, given either preventively or therapeutically, is especially needed in 12 countries with a high incidence of gastric cancer (20), re-infection (22), or antibiotic 13 resistance. However, clinical trials of various oral or parenteral H. pylori vaccine 14 candidates have not shown much promise to date, pointing to the need for identifying 15 improved antigen-adjuvant formulations and/or alternative routes of immunization in the 16 quest for an effective vaccine against H. pylori (33) . 17 18 The importance of cell-mediated mucosal immunity in protection against experimental H. 19 pylori infection after vaccination is well established (1, 9, 10, 23, 35) . In most studies, 20 intragastric (IG) immunization has been used to achieve efficient stimulation of the 21 gastrointestinal immune response. However, this route usually requires large amounts of 22 antigen for efficient immunization and the environment in the stomach and intestine may 23 on November 12, 2017 by guest http://iai.asm.org/
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FTY720 treatment 1
To prevent the egress of T and B cells from lymph nodes (18), mice were injected 2 intraperitoneally with 1µg of FTY720 per gram of body weight (Cayman Chemicals, 3 Michigan, USA) in a final volume of 250µl 3 hours prior to immunization and thereafter 4 every day for 5 days. At the time of sacrifice mononuclear cells were isolated from the 5 blood, stained for CD3 and CD19 (BD Biosciences) and examined by flow cytometry to 6 confirm block of egress of lymph node T and B cells by FTY720. 7
8
Quantitative culture of H. pylori SS1 from the stomach 9
To evaluate bacterial colonization in the stomach of the sacrificed animals, one half of 10 each stomach was homogenized in Brucella broth using a tissue homogenizer (Ultra 11 Turrax; IKA Laboratory Technologies, Staufen, Germany). Serial dilutions of the 12 homogenates were plated on Helicobacter-selective plates. After 7 days of incubation at 13 37°C under microaerophilic conditions, visible colonies with typical H. pylori 14 morphology were counted, and the urease test was performed for any uncertain colonies. 15 Plates with 10-100 colonies were used for calculating the number of bacteria per stomach 16 by multiplying by the appropriate dilution factor (23) . 17
18
Serum antibody responses 19
Blood was collected from the axillary plexus immediately before the mice were killed. 20
Serum antibody titers were determined by ELISA against a membrane antigen 21 preparation of H. pylori strain Hel 305 (MP Hel 305), which was coated overnight at 22 room temperature. Levels of IgG antibodies were measured by testing serial dilutions of 23 on November 12, 2017 by guest http://iai.asm.org/ Downloaded from 1:100 pre-diluted sera followed by detection of bound specific IgG antibodies with 1 horseradish peroxidase (HRP)-coupled goat anti-mouse IgG (Jackson Immuno Research,  2 West Grove, PA, USA) secondary antibody and subsequent reaction with substrate o-3
Phenylenediamine dihydrochloride (OPD) added together with H 2 O 2 and incubated at 4 room temperature for 30 min. The enzymatic reaction was then stopped by adding 1M 5 sulfuric acid, and the absorbance at 490 nm was then measured in a spectrophotometer. 6
The antibody titers are defined as the reciprocal serum dilution giving an absorbance of 7 0.4 above the background. 8 9
Mucosal IgA antibody responses 10
Locally produced IgA antibodies in the stomach and intestinal tissues were determined 11 using the Perfext method (36). Briefly, after sacrifice mice were extensively perfused 12 with heparinized PBS to remove blood from the organs. Tissues were extracted from the 13 stomach and small intestines (a 5 cm intestinal segment approximately 2-7 cm below the 14 pylorus) using a 2% saponin-PBS solution as previously described in detail (23 Hel 305 lysate antigens (10 µg/ml and cultured for 96 hours in Iscove's medium 5 (Biochrome, Berlin, Germany) supplemented with 5% heat-inactivated fetal calf serum 6 (Sigma), 50 µM 2-mercaptoethanol (Sigma), 1 mM L-glutamine (Biochrome), and 50 7 µg/ml gentamicin (Sigma) at 37°C in a 5% CO 2 atmosphere. Supernatants were collected 8 and stored at -70°C for subsequent cytokine analysis. To determine proliferation, the cells 9
were pulsed with 1 µCi of [ 3 H] thymidine (Amersham Bioscience, Buckinghamshire, 10 UK) for the last 6-8 hours of culture. The cellular DNA was collected with a cell 11 harvester (Skatron) on glass fiber filters (Wallac) and assayed for 3 H incorporation using 12 a liquid scintillation counter (Beckman, LKB, Bromma, Sweden). IL-17 was measured 13 in culture supernatants using Duoset cytokine ELISA (R&D Systems, Abingdon, United 14 Kingdom). IFN-γ was measured using the mouse Inflammation Cytometric Bead Array 15 Kit (BD Biosciences) according to the manufacturer's instructions. 16 
17
RNA isolation 18
The stomach was excised and dissected along the greater curvature. Any loose stomach 19 contents were removed by washing in PBS. Two longitudinal strips including the antrum 20 and corpus were cut and placed directly into RNAlater (Qiagen, Hilden, Germany). The 21 samples were kept at 4°C for 2 days and then stored at -70°C. For RNA isolation, the 22 tissue was thawed and transferred to RLT lysis buffer (Qiagen) with 1% β-23 mercaptoethanol and homogenized for 2 min at 30 Hz using Tissue Lyser II (Qiagen). 1 Total RNA was extracted using the RNeasy Mini kit (Qiagen) and stored at -70°C until 2 further analysis. 3 4
Real-time polymerase chain reaction (RT-PCR) 5
RNA (2 µg) was reversely transcribed into cDNA using the Omniscript kit (Qiagen). All 6 real-time PCR reactions were run in 96-well plates using the standard amplification 7 conditions described for the 7500 RT-PCR System and 9 µl cDNA, 10 µl 2x Power 8 SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA), and 1 µl of gene-9 specific oligonucleotide primers (Eurofins MWG Operon, Ebersberg, Germany) ( Table  10 1). The reactions were run in duplicate, and β-actin was used as the reference gene in all 11 experiments. The difference between β-actin and the target gene (∆Ct) was determined, 12 and the relative expression was calculated using the formula 2 ∆Ct . The values were 13 adjusted so that the median in the infection control group was set to 1. The negative 14 control (lacking reverse transcriptase) giving the lowest C T value was used to determine 15 the detection limit. 16
17
Immunohistochemistry 18 Six-micrometer-thin sections of stomach tissue were fixed in acetone and stained using 19 rat anti-mouse CD4 (Clone L3T4) CD8 (Clone Ly-3), MAdCAM-1 (clone MECA 367), 20 CD19 (clone 1D3), or rat IgG2a isotype control antibodies (all from BD) as previously 21 described (26). Sections were evaluated using the Biopix analysis software (BioPix AB, 22 in the H. pylori-specific proliferative response of both MLN (p<0.05) and spleen cells 2 (p<0.01) compared to unimmunized mice and these responses were substantially 3 increased after challenge with H. pylori (Fig. 3A) ; similar responses although less 4 influenced by the challenge were induced by IG immunization (Fig 3B) . We also 5 examined the production of IFN-γ and IL-17 from MLN and spleen cells stimulated with 6
H. pylori antigens from SL immunized mice and found that both of these cytokines and 7
especially IL-17 were increased after challenge, to levels much higher than in infected 8 unimmunized mice (Fig. 3 C) . Our results indicate that SL immunization induces a mixed 9
Th1/Th17 response, with a trend towards production of higher amounts of IL-17 than of 10 IFN-γ after challenge. The results are shown in Fig 4C and demonstrate that protection was much stronger (>20-7 fold) after SL immunization compared to that after pharyngeal immunization. We 8 conclude that swallowed antigen and adjuvant cannot explain the strong immune 9 protection seen against H. pylori after SL immunization. + (data not shown) T cells, in the gastric mucosa of SL immunized and infected 23 mice, whereas little or no cell infiltration was evident in SL immunized but not infected 1 or infected but not immunized mice (Fig. 5A-D) . 2 3 RT-PCR analysis was carried out to study the expression of CD4 + derived cytokines IFN-4 γ and IL-17 in the gastric mucosa of immunized and infected mice compared to 5 unimmunized infection controls at the time of sacrifice. Our results showed significantly 6 elevated levels of both IFN-γ (p<0.001) and IL-17 (p<0.01) transcripts in SL immunized 7 mice compared to unimmunized infected mice, whereas the transcript levels in the 8 stomach mucosa of mice that were SL immunized but not infected did not differ from the 9 levels in naïve mice (Fig. 5 E) . Likewise, the expression of IFN-γ and IL-17 mRNA in 10 the stomachs of mice immunized (ineffectively) with H. pylori lysate antigens without 11 CT adjuvant or with CT without lysate antigens and then infected ( which was significantly increased after infection with H. pylori (Fig. 6 ). In the absence of 22 infection SL immunization tended to modestly stimulate MAdCAM-1 expression but not 23 on November 12, 2017 by guest http://iai.asm.org/ Downloaded from to the same extent as in mice that were first immunized SL and then infected, in which 1 the highest levels of MAdCAM-1 were found (Fig. 6B) . on the cells, CXCR3 and CCR10 (13) . In contrast to the less restricted expression of 9
MAdCAM-1 in relation to infection and immunization, the expression of the CXCL10 10 and CCL28 genes in the stomach mucosa was elevated only in SL immunized and 11 infected mice, and the expression was closely matched by increased levels of their 12 cognate receptors ( Fig. 7A and B) . A similar analysis of the gene expression of CCL25 13 (TECK , Thymus-Expressed ChemoKine), a small intestine-specific chemokine known to 14 attract CCR9 + B and T cells, and of CCR9, the chemokine receptor in the stomach, 15
showed no difference between SL immunized infected mice and unimmunized infection 16 controls (Fig 7C) . Our findings indicate that SL immunization followed by H. pylori 17 infection results in the specific up-regulation of CXCL10 and CCL28 in the stomach, 18 which together with enhanced MAdCAM-1 expression could explain the strong attraction by SL immunization. Our results expand upon previous reports that used SL 15 immunization to induce immune responses in the respiratory and genital tracts (7, 8, 31) 16 by showing that this novel route of mucosal immunization can also be used to induce 17 strong immune responses and protection against infection in the mucosa of the 18 gastrointestinal tract. 19
20
Previous studies using the mouse-adapted H. pylori SS1 strain as the challenge strain for 21 testing the protection afforded by vaccine candidates and adjuvant formulations via the 22 IG route usually achieved a 5-to 10-fold reduction in bacterial load (1, 23, 32) . This 23 reduction is in near agreement with the 6-fold reduction measured in this study after IG 1 immunization with H. pylori lysate antigens and CT adjuvant in bicarbonate buffer. The 2 20-fold reduction in bacterial load found after SL immunization with the same antigen 3 and adjuvant combination, administered to fully anesthetized mice in a 10-microliter 4 volume without any bicarbonate buffer, which is critical for protection after IG 5 immunization (6) argues against the possibility that immune responses and protection 6 against H. pylori infection after SL immunization was to any significant extent induced 7 by swallowed antigen and adjuvant. This conclusion was further supported by directly 8 comparing the levels of protection after SL immunization and corresponding 9 administration of antigen and adjuvant in the posterior pharynx. The latter administration 10 should increase the potential for swallowing, and still SL immunization induced a much 11 stronger protection than the pharyngeal immunization. receptors on the lymphocytes (13) . Recent studies in mice and humans have identified a 22 role for the interaction between the chemokine CXCL10 (IP-10) and chemokine receptor 23 CXCR3 in the specific migration of polarized Th1 CD4 + T cells to inflamed intestinal 1 tissue (24, 29) and a similar role for the interaction between CCL28 (MEC) and CCR10 2 in attracting IgA + plasmablasts to the bronchi, colon, salivary glands, and mammary 3 glands (15) . In SL immunized mice infected with H. pylori, we measured using RT-PCR 4 an increase in the expression of the CXCL10, CXCR3, CCL28, and CCR10 genes in the 5 stomach, whereas expression of the small intestine-specific B and T cell chemoattractant 6 CCL25 (TECK) and its receptor CCR9 (14) was not changed. Thus, our results suggest 7 that, in SL immunized and H. pylori infected mice, CXCR3-expressing Th1 cells and 8 CCR10-expressing IgA + plasmablasts enter the stomach in response to local production 9 of CXCL10 and CCL28, respectively, in the stomach mucosa. In humans, increased 10 expression of CCL28, but not CCL25 was recently reported in H. pylori-infected 11 individuals compared to uninfected individuals that correlated significantly with total IgA 12 antibody levels in the stomach (11). Thus, in the stomach of both H. pylori-infected 13 humans and SL immunized and infected mice, infection-induced inflammation appears to 14 induce specific up-regulation of CXCL10 and CCL28 (but not CCL25), and these 15 chemokines contribute to the migration of lymphocytes into the stomach and protect 16 against H. pylori infection. 17
18
The present study adds to recent reports that the SL mucosa is an attractive site for the 
